Avient Corporation vs Nuwellis Inc — how do they compare? Avient Corporation trades at $35.82 (market cap $3.28B), while Nuwellis Inc trades at $3.22 (market cap $1.17M). The key difference: Avient Corporation is far larger — about 2803.4× Nuwellis Inc's market cap, and Avient Corporation pays a 3.07% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| AVNT | NUWE | |
|---|---|---|
Market Cap | $3.28B | $1.17M |
Sector | Technology | Technology |
52-Week High | $43.28 | $558.26 |
52-Week Low | $27.48 | $2.80 |
Enterprise Value | $4.78B | -$636.97K |
Dividend Yield | 3.07% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NUWE trades at $2.80, down 7.89% in the last session, with a bearish technical outlook from moving averages. The company reported a net loss of $17.52 million in 2025 despite $8.27 million revenue, reflecting a negative net margin of 217.22%. Recent developments include a CEO transition to Mike McCormick, a $6 million public offering in June 2026, and expansion in pediatric care installations, indicating strategic growth efforts amid financial challenges.
The outlook remains high-risk due to persistent losses and negative ROE/ROA, though low P/E and P/B ratios suggest undervaluation. Analyst sentiment is split evenly between buy and hold. Key risks include cash burn from negative operating cash flow and execution hurdles in scaling commercial adoption. Upside depends on revenue acceleration and cost management under new leadership.
Trailing returns across standard periods
Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →